BEAT stock forecast
Our latest prediction for BioTelemetry, Inc.'s stock price was made on the July 27, 2018 when the stock price was at 52.75$.
In the short term (2weeks), BEAT's stock price should underperform the market by -0.20%. During that period the price should oscillate between -5.69% and +4.79%.
In the medium term (3months), BEAT's stock price should underperform the market by -0.91%. During that period the price should oscillate between -12.90% and +13.21%.Get email alerts
Create a solid portfolio with BEAT
About BioTelemetry, Inc.
BioTelemetry, Inc. provides monitoring services and digital population health management in a healthcare setting, medical device manufacturing and centralized core laboratory services for clinical research. The firm also develops proprietary integrated patient management platform that incorporates wireless data transmission network. It operates through the following segments: Healthcare, and Research. The Healthcare segment is focused on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. The Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials. The company was founded on April 22, 2013 and is headquartered in Malvern, PA.
At the moment the company generates 388M USD in revenues.
On its last earning announcement, the company reported a profit of 0.39$ per share.
The book value per share is 8.35$
Three months stock forecastJuly 27, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|